PDA

View Full Version : New study reinforces major advantages of Dako's HER2 IQFISH pharmDx in breast cancer

News
02-17-2014, 03:50 AM
Dako, an Agilent Technologies company and worldwide provider of cancer diagnostics, have announced positive findings in an independent French multicenter study on the performance of Dako's HER2 IQFISH pharmDx(TM).

More... (http://www.medicalnewstoday.com/releases/272710.php)